Nötropenik Kanser Hastalarından İzole Edilen Bakteriyel Ajanların İmipenem Duyarlılıkları

Öz

Hematoloji kliniğinde takip edilen nötropenik kanser hastalarından izole edilen çeşitli bakteriyel ajanların imipeneme duyarlılıkları araştırıldı. İzole edilen toplam 56 bakteriyel etkenin duyarlılık işlemleri agar-disk diffüzyon metoduyla gerçekleştirildi. Etkenlerin 16’sı E. Coli, 10’u Pseudomonas spp, 12’si Enterobacter spp, 5’i Proteus spp, 5’i Klebsiella, 8’i Stafilokok olarak tespit edildi. Bu etkenlerin imipeneme duyarlılıkları sırasıyla 16 E. Coli suşunun 13’ünde (%81,2), 10 Pseudomonas suşunun 8’inde (%80), 12 Enterobacter suşunun 10’unda (%83,3), 5 Proteus suşunun 4’ünde (%80), 5 Klebsiella suşunun 3’ünde (%60), 8 Stafilokok suşunun 6’sında (%75) olarak bulundu.

Sonuç olarak imipenemin, nötropenik kanser hastalarındaki bakteriyel ajanlara karşı önemli oranda duyarlılığı olan bir antibakteriyel olduğu gözlendi. 

Anahtar Kelimeler

• Nötropeni,İmipenem

Susceptibilities of Bacterial Agents Isolated from Neutropenic Cancer Patients to Imipenem

Öz

Susceptibilities of various bacterial agents to imipenem isolated from neutropenic cancer patients followed in the department of Hematology were investigated. Susceptibility procedures of totally 56 isolated bacterial agents were carried out by agar-disc diffusion method. Of the agents ,16 were found as E. Coli, 10 as Pseudomonos spp, 12 as Enterobacter spp, 5 as Proteus spp, 5 as Klebsiella, and 8 as Staphyloccocus. The susceptibility of these agents to Imıpenem was identified in 13 of 16 E. Coli strain (81.2%), 8 of 10 Pseudomonas strain (80%), 10 of 12 Enterobacter strain (83.3%), 4 of 5 Proteus strain (80%), 3 of 5 Klebsiella strain (60%) and 6 of 8 Staphyloccocus strain (75%).

Consequently, it was observed that Imipenem is an antibacterial agent that has significant efficacy against bacterial agents in neutropenic cancer patients. 

Anahtar Kelimeler

• Neutropenia,Imipenem

Kaynakça

1. Barza M. Imipenem: First of a new class of β-lactam antibiotics. Ann Intern Med. 1985;103:552-560.
2. Bauer AW, Kirby WMM, Scherris JC, Turck M. Antibiotic susceptibility testing by a standardized single method. Am J Clin Path. 1986;45:493-496.
3. Bodey GP. Antibiotics in patients with neutropenia. Arch Intern Med. 1984;144(9):1845-1851. doi:10.1001/archinte.1984.00350210173029
4. Bodey GP, Alvarez ME, Jones PG et al. Imipenem-cilastatin as initial therapy for febrile cancer patients. Antimicrob Agents Chemother. 1986;30(2):211-214. doi:10.1128/aac.30.2.211
5. Gaynes RP, Culver DH. Resistance to imipenem among selected Gram negative bacilli in the United States. Infect Control Hosp Epidemiol. 1992;13(1):10-14. doi:10.1086/646417
6. Kahan FM, Krupp H, Sundeluf JG, Birnbaum J. Thienamycin: development of imipenem- cilastatin. J Antimicrob Chemother. 1983;12:1-35.
7. Kocabeyoğlu Ö, Koşan E, Birinci İ, Kanmaz M, Yılmaz M. İmipenemin çeşitli bakteri suşlarına etkinliğinin mikrodilüsyon yöntemiyle araştırılması. ANKEM Derg. 1994;8(1):36-39.
8. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing. Fourth Information Supplement. NCCLS Document M 100-S4. NCCLS, Villanova, PA, USA; 1992.

9. Neu HC, Labthavikul P. Comparative in vitro activity of N-formimidoyl thienamycin against gram positive and gram negative aerobic and anerobic species and its beta-lactamase stability. Antimicrob Agents Chemother. 1982;21(1):180-187.
10. Schimpff S, Satterlee W, Young VM, et al. Empiric therapy with Carbenicilin and gentamisin for febrile patients with cancer and granlocytopenia. N Engl J Med. 1971;284(19):1061-1065.
11. Watanabe X Hirumu R, Katsu K. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime and cefpirome against ceftazdime or imipenem rezistant Pseudomonas aerugmosa. J Antimicrob Chemother. 1992;30(5):633-641.